Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1183]

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Durvalumab with BCG and maintenance therapy improves disease-free survival in...

Dr Maria De Santis - Charité University Hospital, Berlin, Germany

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC ( Dr Maria De Santis - Charité University Hospital, Berlin, Germany )

Perioperative enfortumab vedotin plus pembro improves survival and pCR in...

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )

Avelumab maintenance after reduced chemotherapy cycles improves QoL without...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland...

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer ( Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland, USA )

ADT with PORT is a good treatment option for men with unfavourable intermediate...

Dr Mack Roach III - University of California San Francisco, San Francisco, USA

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC ( Dr Mack Roach III - University of California San Francisco, San Francisco, USA )

Non-clear cell renal cell carcinoma: Management of papillary RCC

Prof Camillo Porta and Prof Laurence Albiges

Non-clear cell renal cell carcinoma: Management of papillary RCC ( Prof Camillo Porta and Prof Laurence Albiges )

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA

The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Dr Ricky Frazer and Dr Rebecca Dobson

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective ( Dr Ricky Frazer and Dr Rebecca Dobson )

More from ecancer